MiRNA-103/107 in Primary High-Grade Serous Ovarian Cancer and Its Clinical Significance
1
Department of Operative Gynecology, Endoscopy and Gynecologic Oncology, Polish Mother’s Memorial Hospital Research Institute, 281 Rzgowska Str., 93-338 Lodz, Poland
2
Institute of Medical Biology, Polish Academy of Sciences, 106 Lodowa Str., 93-232 Lodz, Poland
3
Department of Molecular Medicine, Medical University of Lodz, Al. Kościuszki 4, 90-419 Lodz, Poland
4
Department of Clinical Pathology, Polish Mothers’ Memorial Hospital-Research Institute, 281 Rzgowska Str., 93-338 Lodz, Poland
5
The Central Laboratory of Medical University in Lodz, 6/8 Mazowiecka Str., 92-215 Lodz, Poland
6
Gynecologic Oncology Center, Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, 128 00 Prague, Czech Republic
7
Department of Surgical and Endoscopic Gynecology, Medical University in Lodz, Al. Kościuszki 4, 90-419 Lodz, Poland
*
Author to whom correspondence should be addressed.
Cancers 2020, 12(9), 2680; https://doi.org/10.3390/cancers12092680
Received: 21 August 2020
/
Revised: 14 September 2020
/
Accepted: 17 September 2020
/
Published: 19 September 2020
(This article belongs to the Special Issue MicroRNA and Cancer)
Simple Summary
MiRNA-103/107-DICER axis may be one of the key regulators of cancer aggressiveness. Data on miRNA-103/107 in high grade serous ovarian cancer is scarce. We aimed to assess miRNA-103/107 expression levels in high grade serous ovarian cancer tissues and relate them to patients’ clinicopathological data. MiRNA-103/107, DICER expression levels were also evaluated in selected ovarian cancer cell lines. Clinical and prognostic significance of miRNA-103/107 was not confirmed in our study. However, the results of our study support the possible existence of miRNA-103/107- DICER axis in ovarian cancer.
High levels of miRNA-103/107 are associated with poor outcomes in the case of breast cancer patients. MiRNA-103/107-DICER axis may be one of the key regulators of cancer aggressiveness. MiRNA-103/107 expression levels have never been related to patients’ clinicopathological data in epithelial ovarian cancer. We aimed to assess miRNA-103/107 expression levels in high grade serous ovarian cancer tissues. Expression levels of both miRNAs were related to the clinicopathological features and survival. We also evaluated expression levels of miRNA-103/107 and DICER in selected ovarian cancer cell lines (A2780, A2780cis, SK-OV-3, OVCAR3). We assessed the relative expression of miRNA-103/107 (quantitative reverse transcription-polymerase chain reaction) in fifty archival formalin-fixed paraffin-embedded tissue samples of primary high grade serous ovarian cancer. Then, miRNA-103/107 and DICER expression levels were evaluated in selected ovarian cancer cell lines. Additionally, DICER, N-/E-cadherin protein levels were assessed with the use of western blot. We identified miRNA-107 up-regulation in ovarian cancer in comparison to healthy tissues (p = 0.0005). In the case of miRNA-103, we did not observe statistically significant differences between cancerous and healthy tissues (p = 0.07). We did not find any correlations between miRNA-103/107 expression levels and clinicopathological features. Kaplan–Meier survival (disease-free and overall survival) analysis revealed that both miRNAs could not be considered as prognostic factors. SK-OV-3 cancer cell lines were characterized by high expression of miRNA-103/107, relatively low expression of DICER (western-blot), and relatively high N-cadherin levels in comparison to other ovarian cancer cell lines. Clinical and prognostic significance of miRNA-103/107 was not confirmed in our study.
View Full-Text
Keywords:
miRNA; ovarian cancer; survival; prognostic factor
▼
Show Figures
Figure 1
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
MDPI and ACS Style
Wilczynski, M.; Kielbik, M.; Senderowska, D.; Krawczyk, T.; Szymanska, B.; Klink, M.; Bieńkiewicz, J.; Romanowicz, H.; Frühauf, F.; Malinowski, A. MiRNA-103/107 in Primary High-Grade Serous Ovarian Cancer and Its Clinical Significance. Cancers 2020, 12, 2680. https://doi.org/10.3390/cancers12092680
AMA Style
Wilczynski M, Kielbik M, Senderowska D, Krawczyk T, Szymanska B, Klink M, Bieńkiewicz J, Romanowicz H, Frühauf F, Malinowski A. MiRNA-103/107 in Primary High-Grade Serous Ovarian Cancer and Its Clinical Significance. Cancers. 2020; 12(9):2680. https://doi.org/10.3390/cancers12092680
Chicago/Turabian StyleWilczynski, Milosz, Michal Kielbik, Daria Senderowska, Tomasz Krawczyk, Bozena Szymanska, Magdalena Klink, Jan Bieńkiewicz, Hanna Romanowicz, Filip Frühauf, and Andrzej Malinowski. 2020. "MiRNA-103/107 in Primary High-Grade Serous Ovarian Cancer and Its Clinical Significance" Cancers 12, no. 9: 2680. https://doi.org/10.3390/cancers12092680
Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
